LCM
HTGM

Laurion Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Laurion Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,086
Closed -$332K – 1939
2017
Q3 		$332K Buy
+1,086
New +$412K ﹤0.01% 1306

Other funds holding HTGM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurion Capital Management's HTGM Position: Q4 2017 in Review

Laurion Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2017, closing a stake of 1,086 shares — an estimated $332K sold.

Laurion Capital Management first reported a position in HTGM in Q3 2017 and held it in 1 quarter. The position peaked at $332K in Q3 2017. 17 funds tracked by Wall St. Rank hold HTGM as of Q4 2017.

  • Laurion Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 1,086 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2017, an estimated $332K.
  • Laurion Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Laurion Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $332K in Q3 2017.
  • 17 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.